Target Name: FKTN
NCBI ID: G2218
Review Report on FKTN Target / Biomarker Content of Review Report on FKTN Target / Biomarker
FKTN
Other Name(s): Fukuyama type congenital muscular dystrophy protein | Fukutin, transcript variant 1 | MDDGB4 | FCMD | FKTN variant 1 | Fukuyama-type congenital muscular dystrophy protein | Fukutin | CMD1X | FKTN_HUMAN | Ribitol-5-phosphate transferase | LGMDR13 | LGMD2M | MDDGA4 | Ribitol-5-phosphate transferase FKTN (isoform a) | Fukutin, transcript variant 2 | fukutin | MDDGC4 | FKTN variant 2 | ribitol-5-phosphate transferase | patient fukutin

FKTN Gene as Potential Drug Target/biomarker for Muscle-related Conditions

FKTN (Fukuyama type congenital muscular dystrophy protein) is a gene that has been identified as a potential drug target or biomarker for the treatment of a range of muscle-related conditions, including muscular dystrophy, myopathies, and neuromuscular disorders.

The FKTN gene is a member of the superfamily of actinin-repeat containing genes (SARG), which are characterized by the presence of a unique repetitive unit called a nucleotide-binding oligomerization domain (NBO domain). The NBO domain is a structural element that is found in a variety of proteins, including actinin-repeat containing genes, and is involved in the regulation of protein stability and function.

In addition to its potential drug-targeting properties, FKTN has also been identified as a potential biomarker for a number of muscle-related conditions. The FKTN gene has been shown to be expressed in muscle tissue and is involved in the production of the protein FKTN , which is known to play a role in the regulation of muscle cell survival and growth.

While further research is needed to fully understand the potential therapeutic uses of FKTN, studies have shown that the NBO domain is a key factor in its regulation and that changes in the levels of FKTN protein expression may be associated with the development of muscle-related conditions.

One potential mechanism by which FKTN may be used to treat muscle-related conditions is by modulating the activity of cells involved in muscle development and maintenance. For example, studies have shown that FKTN can interact with the protein Myosin, which is involved in muscle contraction and relaxation. By modulating the activity of Myosin, FKTN may be able to influence muscle contractions and could potentially be used to treat muscle-related conditions.

Another potential mechanism by which FKTN may be used to treat muscle-related conditions is by targeting the genes involved in muscle development and maintenance. For example, studies have shown that FKTN can interact with the gene Mygene, which is involved in muscle growth and development. By modulating the activity of My gene, FKTN may be able to influence muscle growth and development and could potentially be used to treat muscle-related conditions.

In conclusion, FKTN is a gene that has the potential to be a drug target or biomarker for the treatment of a range of muscle-related conditions. Further research is needed to fully understand its regulatory mechanisms and to determine its potential therapeutic uses.

Protein Name: Fukutin

Functions: Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:29477842, PubMed:27194101). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligand binding moiety composed of repeats of 3-xylosyl-alpha-1,3-glucuronic acid-beta-1 (PubMed:17034757, PubMed:25279699, PubMed:26923585, PubMed:29477842, PubMed:27194101). Required for normal location of POMGNT1 in Golgi membranes, and for normal POMGNT1 activity (PubMed:17034757). May interact with and reinforce a large complex encompassing the outside and inside of muscle membranes (PubMed:25279699). Could be involved in brain development (Probable)

The "FKTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FKTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9 | FNIP1 | FNIP2 | FNTA | FNTB | FOCAD | Focal Adhesion Kinases (FAK) | Folate Receptor | FOLH1 | FOLH1B | Follicle stimulating hormone | FOLR1 | FOLR2 | FOLR3 | Formin homology 2 domain-containing proteins